68Ga somatostatin analog radiolabelling: The radiopharmacist's point of view

C. Lamesa (1) , A. Rauscher (1) , Franck Lacœuille (2, 3) , M.-D. Desruet , B. Guillet , Alain Faivre-Chauvet (1)

1 CRCINA-ÉQUIPE 13 - Nuclear Oncology
2 MINT - Micro et Nanomédecines Biomimétiques
3 CHU Angers - Centre Hospitalier Universitaire d'Angers

68Ga-labelled peptides imaging has emerged during the last decade. This was possible thanks to innovative development in 68Ge/68Ga generator or bifunctional chelates (BFC) able to complex 68Ga and to be linked to various peptides and thus optimize radiolabelling procedures. This present review focuses on radiolabelling of somatostatine (SMS) analogs with 68Ga for clinical applications. In that sense, is discussed the key parameters influencing the radiolabelling, from the elution of 68Ge/68Ga generator to purification of final product, and through the quality control of 68Ga-SMS analog radiopharmaceuticals, as well as the full automation of the radiolabelling process.

Domaines: Sciences du Vivant [q-bio]

C. Lamesa, A. Rauscher, Franck Lacœuille, M.-D. Desruet, B. Guillet, et al.. 68Ga somatostatin analog radiolabelling: The radiopharmacist's point of view. Médecine Nucléaire - Imagerie Fonctionnelle et Métabolique, 2015, 39 (1), pp.3-10. ⟨10.1016/j.mednuc.2015.01.003⟩. ⟨hal-01392434⟩